

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
GlaxoSmithKline LLC	FORMERLY SmithKline Beecham Corporation	10/28/2009	LIMITED LIABILITY COMPANY: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ViiV Healthcare Company		
<b>Street Address:</b>	Corporation Service Company		
<b>Internal Address:</b>	2711 Centerville Road Suite 400		
<b>City:</b>	Wilmington		
<b>State/Country:</b>	DELAWARE		
<b>Postal Code:</b>	19808		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	3801611	VIIV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(704)625-9190		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	919 483 1803		
<b>Email:</b>	trademarks@gsk.com		
<b>Correspondent Name:</b>	Maribeth Day Case		
<b>Address Line 1:</b>	LGTM, C.3157.3D		
<b>Address Line 2:</b>	Five Moore Drive		
<b>Address Line 4:</b>	Research Triangle Pa, NORTH CAROLINA 27709		
<b>ATTORNEY DOCKET NUMBER:</b>	PRJ-COA-7043127/084/PDJ		
<b>NAME OF SUBMITTER:</b>	Maribeth Day Case		
<b>Signature:</b>	/Maribeth Day Case/		

CH \$40.00 3801611

Date:

08/05/2011

**Total Attachments: 18**

source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page1.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page2.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page3.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page4.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page5.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page6.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page7.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page8.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page9.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page10.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page11.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page12.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page13.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page14.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page15.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page16.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page17.tif  
source=Assignment - GSK LLC - ViiV Healthcare Company\_28 Oct 2009#page18.tif

Dated October 28<sup>th</sup> 2009

GLAXOSMITHKLINE LLC

- and -

VIIV HEALTHCARE COMPANY

---

TRADE MARK ASSIGNMENT DEED

---

Slaughter and May  
One Bunhill Row  
London EC1Y 8YY  
(SXXM/SPW)

TP092780070

**TRADEMARK**  
**REEL: 004599 FRAME: 0052**

THIS DEED is made the 28<sup>th</sup> day of October 2009

**BETWEEN:**

- (1) **GLAXOSMITHKLINE LLC** (formerly known as SmithKline Beecham Corporation of One Franklin Plaza, 200 N. 16<sup>th</sup> Street, Philadelphia PA 19102 USA) whose EIN number is 23-1099050 and whose registered office is at Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, New Castle, Delaware 19808 USA (the “Assignor”); and
- (2) **VIIV HEALTHCARE COMPANY** (registered number 4672617) whose registered office is at Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, New Castle, Delaware 19808 USA (the “Assignee”).

**WHEREAS:**

- (A) Each of the Assignor and the Assignee is a member of GSK's Group.
- (B) By a deed dated on or about 26 October 2009, Glaxo Group Limited assigned the GGL Marks to the Assignor. The Assignor's ownership of the GGL Marks has not yet been recorded at the relevant intellectual property registries.
- (C) By a deed dated on or about 26 October 2009, SmithKline Beecham p.l.c. (now known as SmithKline Beecham Limited) assigned the SBL Marks to the Assignor. The Assignor's ownership of the SBL Marks has not yet been recorded at the relevant intellectual property registries.
- (D) By a deed dated on or about 26 October 2009, Montrose Fine Chemical Company Limited assigned the Montrose Mark to the Assignor. The Assignor's ownership of the Montrose Mark has not yet been recorded at the relevant intellectual property registry.
- (E) Pursuant to the SPA, GSK has agreed to sell to Mercury the entire issued share capital in the Assignee and has agreed to procure that, prior to that sale, the Trade Marks are transferred to the Assignee.
- (F) In order to give effect to the GlaxoSmithKline Reorganisation, the Assignor has agreed to transfer to the Assignee the Trade Marks.

**NOW THIS DEED WITNESSETH** as follows:

**1. Interpretation**

1.1 In this Deed:

“GlaxoSmithKline Reorganisation” has the meaning given in the SPA;

“Group” has the meaning given in the SPA;

- “GGL Marks”** means the trade mark registrations and applications for registration listed in Part 2 of the Schedule;
- “GSK”** means GlaxoSmithKline plc (a company incorporated in England and Wales with registered number 03888792), whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS;
- “LLC Mark”** means the trade mark registration listed in Part 1 of the Schedule;
- “Mercury”** means ViiV Healthcare Limited (a company incorporated in England and Wales with registered number 06876960), whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS;
- “Montrose Mark”** means the trade mark registration listed in Part 4 of the Schedule;
- “SBL Marks”** the trade mark registrations and applications for registration listed in Part 3 of the Schedule;
- “SPA”** means the Agreement for the Sale and Purchase of the Share Capital of Pfizer-1, Pfizer UK Newco, Pfizer SPV, the Assignee and Mercury Healthcare UK (No. 2) Limited dated 16 April 2009 between Pfizer Inc., GSK and Mercury; and
- “Trade Marks”** means the LLC Mark, the GGL Marks, the SBL Marks and the Montrose Mark.

1.2 In this Deed, unless otherwise specified, references to Clauses and Schedules are to clauses of and schedules to this Deed and headings to Clauses and Schedules are for convenience only and do not affect the interpretation of this Deed.

## 2. Assignment

2.1 The Assignor does hereby assign unto the Assignee, and the Assignee hereby accepts, all the Assignor's right, title and interest in and to the Trade Marks together with all goodwill of the business in relation to which such Trade Marks are used (but no other or greater goodwill) to hold unto the Assignee absolutely.

2.2 The assignment made pursuant to Clause 2.1 includes all rights, privileges and advantages attaching to the Trade Marks, including, without limitation, the portion of Assignor's business to which those Trade Marks pertain and the right to take proceedings and recover damages and obtain all other remedies in respect of past infringements thereof.

**3. No Warranties**

Without prejudice to the terms of the SPA, the Assignee acknowledges that the Assignor does not give any representation, warranty, indemnity or guarantee under this Deed in respect of any of the Trade Marks.

**4. Further Assurance**

The Assignor shall, at the request and cost of the Assignee, execute any further documents that may be necessary to secure the vesting in the Assignee of all rights assigned to the Assignee hereunder.

**5. Counterparts**

This Deed may be executed in any number of counterparts, and by the Assignor and the Assignee on separate counterparts, but shall not be effective until each party has executed at least one counterpart. Each counterpart shall constitute an original of this Deed, but the counterparts shall together constitute but one and the same instrument.

**6. Governing Law and Jurisdiction**

6.1 This Deed shall be governed by and construed in accordance with English law. Any matter, claim or dispute arising out of or in connection with this Deed, whether contractual or non-contractual, is to be governed by and determined in accordance with English law.

6.2 The courts of England are to have jurisdiction to settle any matter, claim or dispute arising out of or in connection with this Deed and the parties hereby submit to the jurisdiction of the English courts. Each party waives (and agrees not to raise) any objection, on the ground of *forum non conveniens* or on any other ground, to the taking of proceedings in relation to any such matter, claim or dispute in the courts of England.

**IN WITNESS** of which this document has been executed and delivered as a Deed on the date first written above.

**THE SCHEDULE**

**Part 1      The LLC Mark**

<b>Country</b>	<b>Mark</b>	<b>Registration No.</b>	<b>Application Date</b>	<b>Registration Date</b>	<b>Class(es)</b>	<b>Status</b>
USA	RETROVIR	1418913	01 May 86	02 Dec 86	5	Registered

**Part 2            The GGL Marks**

*TP092780027*





**Part 3** The SBL Marks

*TP092780055*



**Part 4**      **The Montrose Mark**

Country	Mark	Registration No.	Application Date	Registration Date	Class(es)	Status
Argentina	TELZIR	1930065	29 May 01	26 Jun 03	5	Registered

Executed as a Deed by )  
**GLAXOSMITHKLINE LLC** )  
 acting by its authorised signatory(ies) )  
 who, in accordance with the laws of the territory )  
 in which GlaxoSmithKline LLC )  
 is incorporated is/are acting under the )  
 authority of GlaxoSmithKline LLC )

  
 (Authorised Signatory) William J. Mosher Vice  
 President & Secretary  
  
 (Authorised Signatory) Arlene Sothorn, Assistant Secretary

Executed as a Deed by )  
**VIIV HEALTHCARE COMPANY** )  
 acting by its authorised signatory(ies) )  
 who, in accordance with the laws of the territory )  
 in which ViiV Healthcare Company )  
 is incorporated is/are acting under the )  
 authority of ViiV Healthcare Company )

  
 (Authorised Signatory) William J. Mosher, President &  
 Secretary.  
  
 (Authorised Signatory) Arlene Sothorn, Assistant Secretary

TP092780070

Country/Jurisdiction	Registered Owner	Mark (Profile)	Application #	App. Date	Registration #	Reg. Date	TM Status
USA	Glaxo Group Limited	3TC	78247099	08/May/2003	2823526	16/Mar/2004	Registered
USA	Glaxo Group Limited	AGENERASE	75366369	01/Oct/1997	2317064	08/Feb/2000	Registered
USA	Glaxo Group Limited	A POSITIVE LIFE	77087597	22/Jun/2007	3544143	09/Dec/2008	Registered
USA	Glaxo Group Limited	A POSITIVE LIFE	77087599	22/Jun/2007	3544144	09/Dec/2008	Registered
USA	Glaxo Group Limited	CERZIVIR	78186909	20/Nov/2002	2926308	15/Feb/2005	Registered
USA	Glaxo Group Limited	COMBIVIR	75244811	20/Feb/1997	2158546	19/May/1998	Registered
USA	Glaxo Group Limited	EPIVIR	74213040	11/Oct/1991	1981308	18/Jun/1996	Registered
USA	Glaxo Group Limited	EPIVIR	78906783	13/Jun/2006	3227835	10/Apr/2007	Registered
USA	Glaxo Group Limited	EPIVIR-HBV	75497099	03/Jun/1998	2300910	14/Dec/1999	Registered
USA	Glaxo Group Limited	EPZICOM	78372750	23/Feb/2004	3017368	22/Nov/2005	Registered
USA	Glaxo Group Limited	HIV ORBITAL device	76032462	24/Apr/2000	2970948	19/Jul/2005	Registered
USA	Glaxo Group Limited	HIV ORBITAL device (in colour)	78535439	20/Dec/2004	3152017	03/Oct/2006	Registered
USA	Glaxo Group Limited	HOPE AFTER HIV	77433552	27/Mar/2008	3611275	28/Apr/2009	Registered
USA	Glaxo Group Limited	HOPE AFTER HIV device	77467863	07/May/2008	3611381	28/Apr/2009	Registered
USA	Glaxo Group Limited	TRIZIVIR	75726576	10/Jun/1999	2379199	22/Aug/2000	Registered
USA	Glaxo Group Limited	TRIZIVIR	78224812	12/Mar/2003	2966217	12/Jul/2005	Registered
USA	Glaxo Group Limited	UNA VIDA POSITIVA	77506148	24/Jun/2008			Application
USA	Glaxo Group Limited	UNA VIDA POSITIVA	77506153	24/Jun/2008			Application
USA	Glaxo Group Limited	VIV	77483893	27/May/2008			Application
USA	Glaxo Group Limited	VIVV	77483796	27/May/2008			Application
USA	Glaxo Group Limited	ZIAGEN	75262534	25/Mar/1997	2248121	25/May/1999	Registered
USA	Glaxo Group Limited	ZORASE	76470656	27/Nov/2002	3161252	24/Oct/2006	Registered
USA	Glaxo Group Limited	ZORASE	78066201	29/May/2001	2963046	21/Jun/2005	Registered
UK	Glaxo Group Limited	PROTELZIR	2330729	28/Apr/2003	2330729	28/Apr/2003	Registered
UK	Glaxo Group Limited	STELZIR	2325466	05/Mar/2003	2325466	05/Mar/2003	Registered

Country/Jurisdiction	Registered Owner	Mark (Profile)	Application #	App. Date	Registration #	Reg. Date	TM Status
Aruba	Glaxo Group Limited	TELZIR	IM03121232	12/Dec/2003	22759	01/Mar/2004	Registered
Australia	Glaxo Group Limited	TELZIR	877195	28/May/2001	877195	28/May/2001	Registered
Bahrain	Glaxo Group Limited	TELZIR	39977	08/Nov/2003	39977	08/Nov/2003	Registered
Bolivia	Glaxo Group Limited	TELZIR	0012429	31/Oct/2003	97979C	20/Jan/2005	Registered
Botswana	Glaxo Group Limited	TELZIR	0400129	08/Mar/2004	BWM0400129	08/Mar/2004	Registered
Brazil	Glaxo Group Limited	TELZIR	823942864	28/May/2001	823942864	03/Jul/2007	Registered
Canada	Glaxo Group Limited	TELZIR	1104192	25/May/2001	644590	19/Jul/2005	Registered
Chile	Glaxo Group Limited	TELZIR	529090	25/May/2001	653784	06/Jan/2003	Registered
China (Peoples Republic)	Glaxo Group Limited	TELZIR	2001089837	30/May/2001	1907188	21/Aug/2002	Registered
Colombia	Glaxo Group Limited	TELZIR	2001063790	08/Aug/2001	288612	24/Mar/2004	Registered
Costa Rica	Glaxo Group Limited	TELZIR	40502001	30/May/2001	65857978	09/Jan/2002	Registered
Cuba	Glaxo Group Limited	TELZIR	846156	17/Mar/2005	846156	17/Mar/2005	Registered
Czech Republic	Glaxo Group Limited	TELZIR	167825	29/May/2001	243598	23/Apr/2002	Registered
Dominican Republic	Glaxo Group Limited	TELZIR	2002159398	28/May/2001	129899	30/Aug/2001	Registered
Ecuador	Glaxo Group Limited	TELZIR	113982	29/May/2001	1396801	30/Oct/2001	Registered
El Salvador	Glaxo Group Limited	TELZIR	2004042153	27/Jul/2004			Application
EU	Glaxo Group Limited	TELZIR	002234789	29/May/2001	002234789	01/Oct/2002	Registered
Ghana	Glaxo Group Limited	TELZIR	34726	03/Dec/2003	34726	03/Dec/2003	Registered
Guatemala	Glaxo Group Limited	TELZIR	200103633	25/May/2001	113243	02/Oct/2001	Registered
Guyana	Glaxo Group Limited	TELZIR	20081C	23/Jan/2004	20081C	09/Feb/2004	Registered
Honduras	Glaxo Group Limited	TELZIR	21382001	28/May/2001	83443	15/Jan/2002	Registered
Hong Kong	Glaxo Group Limited	TELZIR	08627001	30/May/2001	26282002	30/Nov/2000	Registered
Hungary	Glaxo Group Limited	TELZIR	M0103026	28/May/2001	170719	12/Jan/2002	Registered
Iceland	Glaxo Group Limited	TELZIR	17382001	25/May/2001	8182001	01/Aug/2001	Registered
India	Glaxo Group Limited	TELZIR	1012462	28/May/2001	1012462	28/May/2001	Registered

Country/Jurisdiction	Registered Owner	Mark (Profile)	Application #	App. Date	Registration #	Reg. Date	TM Status
Indonesia	Glaxo Group Limited	TELZIR	D000112280	11/Jun/2001	505630	17/Apr/2002	Registered
Iran	Glaxo Group Limited	TELZIR	8210069	23/Dec/2003	111018	10/May/2004	Registered
Iraq	Glaxo Group Limited	TELZIR	47167	21/Dec/2004	47167	25/Jun/2008	Registered
Ireland	Glaxo Group Limited	TELZIR	200401455	07/Jul/2004	230138	07/Jul/2004	Registered
Jamaica	Glaxo Group Limited	TELZIR	57885	25/May/2001	39014	25/May/2001	Registered
Japan	Glaxo Group Limited	TELZIR	2001047833	28/May/2001	4535675	11/Jan/2002	Registered
Kazakhstan	Glaxo Group Limited	TELZIR	39775	10/Jul/2007	27970	15/Jan/2009	Registered
Kenya	Glaxo Group Limited	TELZIR	55387	18/Nov/2003	55387	18/Nov/2003	Registered
Kuwait	Glaxo Group Limited	TELZIR	62607	12/Jan/2004	51940	12/Jan/2004	Registered
Libya	Glaxo Group Limited	TELZIR	11536	27/May/2007			Application
Liechtenstein	Glaxo Group Limited	TELZIR		30/May/2001	12169	22/Aug/2001	Registered
Malawi	Glaxo Group Limited	TELZIR	5282003	06/Nov/2003			Application
Mauritius	Glaxo Group Limited	TELZIR	MJM0301261	18/Nov/2003	008642005	18/Nov/2003	Registered
Mexico	Glaxo Group Limited	TELZIR	487471	25/May/2001	756831	30/Jul/2003	Registered
Morocco	Glaxo Group Limited	TELZIR	89262	25/Nov/2003	89262	25/Nov/2003	Registered
Netherlands Antilles	Glaxo Group Limited	TELZIR	300685	08/Dec/2003	10318	12/Feb/2004	Registered
New Zealand	Glaxo Group Limited	TELZIR	638635	28/May/2001	□□□□□□□□9/Nov/2001	29/Nov/2001	Registered
Nicaragua	Glaxo Group Limited	TELZIR	200101817	25/May/2001	52565	13/Feb/2002	Registered
Nigeria	Glaxo Group Limited	TELZIR	TP505162001	15/Jun/2001	67090	05/Jun/2001	Registered
Norway	Glaxo Group Limited	TELZIR	200106722	28/May/2001	213029	21/Feb/2002	Registered
OAPI (African Union)	Glaxo Group Limited	TELZIR	3200102802	30/May/2001	44888	15/Nov/2001	Registered
Oman	Glaxo Group Limited	TELZIR	31885	22/Nov/2003	31885	03/Apr/2006	Registered
Pakistan	Glaxo Group Limited	TELZIR	171294	26/May/2001	171294	26/May/2001	Registered
Panama	Glaxo Group Limited	TELZIR	13228001	11/Dec/2003	132280	11/Dec/2003	Registered
Paraguay	Glaxo Group Limited	TELZIR	29116	07/Nov/2003	268185	24/May/2004	Registered

Country/Jurisdiction	Registered Owner	Mark (Profile)	Application #	App. Date	Registration #	Reg. Date	TM Status
Peru	Glaxo Group Limited	TELZIR	128705	25/May/2001	075053	19/Sep/2001	Registered
Philippines	Glaxo Group Limited	TELZIR	42001003768	31/May/2001			Application
Poland	Glaxo Group Limited	TELZIR	236252	30/May/2001	157942	30/May/2001	Registered
Russian Federation	Glaxo Group Limited	TELZIR	2001717172	08/Jun/2001	256046	26/Sep/2003	Registered
Saudi Arabia	Glaxo Group Limited	TELZIR	86253	16/Nov/2003	74875	22/Sep/2004	Registered
Slovak Republic	Glaxo Group Limited	TELZIR	16492001	29/May/2001	200357	09/Sep/2002	Registered
South Africa	Glaxo Group Limited	TELZIR	200109363	30/May/2001	200109363	30/Nov/2000	Registered
South Korea (Republic of)	Glaxo Group Limited	TELZIR	40200123442	30/May/2001	40531398	01/Oct/2002	Registered
Sudan	Glaxo Group Limited	TELZIR	32197	01/Dec/2003	32197	01/Dec/2003	Registered
Switzerland	Glaxo Group Limited	TELZIR	053422001	29/May/2001	491126	29/May/2001	Registered
Taiwan	Glaxo Group Limited	TELZIR	90021742	30/May/2001	978611	01/Jan/2002	Registered
Tanganyika (Tanzania Republic)	Glaxo Group Limited	TELZIR	QTM001142	10/Dec/2003	30511	10/Dec/2003	Registered
Tangiers	Glaxo Group Limited	TELZIR	29209	08/Dec/2003	29209	08/Dec/2003	Registered
Thailand	Glaxo Group Limited	TELZIR	455017	30/May/2001	TM162867	04/Jul/2002	Registered
Trinidad and Tobago	Glaxo Group Limited	TELZIR	34422	10/Nov/2003	34422	14/Jul/2004	Registered
Turkey	Glaxo Group Limited	TELZIR	2001010294	01/Jun/2001	2001010294	01/Jun/2001	Registered
Uganda	Glaxo Group Limited	TELZIR	26266	04/Dec/2003	26266	04/Dec/2003	Registered
UK	Glaxo Group Limited	TELZIR	2254484	30/Nov/2000	2254484	30/Nov/2000	Registered
Ukraine	Glaxo Group Limited	TELZIR	200508593	28/Jul/2005	76376	25/Apr/2007	Registered
United Arab Emirates	Glaxo Group Limited	TELZIR	57586	13/Dec/2003	89142	03/Jun/2008	Registered
Uruguay	Glaxo Group Limited	TELZIR	350945	31/Oct/2003	350945	19/Dec/2005	Registered
Venezuela	Glaxo Group Limited	TELZIR	936001	31/May/2001	P240770	11/Nov/2002	Registered
WIPO	Glaxo Group Limited	TELZIR	846156	17/Mar/2005	846156	17/Mar/2005	Registered
Zambia	Glaxo Group Limited	TELZIR	6472003	23/Dec/2003	6472003	23/Dec/2003	Registered
Zanzibar (Tanzania Republic)	Glaxo Group Limited	TELZIR	3672003	21/Nov/2003	03672003	21/Nov/2003	Registered

Country/Jurisdiction	Registered Owner	Mark (Profile)	Application #	App. Date	Registration #	Reg. Date	TM Status
Zimbabwe	Glaxo Group Limited	TELZIR	1082004	06/Feb/2004	1082004	06/Feb/2004	Registered
Japan	Glaxo Group Limited	TELZIR in katakana	2002026633	03/Apr/2002	4641412	04/Mar/2003	Registered
Kazakhstan	Glaxo Group Limited	TELZIR in russian cyrillic	39964	26/Jul/2007	28002	15/Jan/2009	Registered
Russian Federation	Glaxo Group Limited	TELZIR in russian cyrillic	2006722430	08/Aug/2006	337471	16/Nov/2007	Registered
Ukraine	Glaxo Group Limited	TELZIR in ukrainian cyrillic	200508592	28/Jul/2005	75375	25/Apr/2007	Registered
Qatar	Glaxo Group Limited	TELZIR with arabic	31117	07/Dec/2003	31117	22/Nov/2006	Registered

TP092780027



Trade Mark	Country	Application #	App. Date	Registration #	Reg. Date
LEXIVA	Argentina	2187240	17/Nov/1998	2087648	19/May/2006
LEXIVA	Bahrain	224398	09/Dec/1998	24861	09/Dec/1998
LEXIVA	Bangladesh	57961	18/Nov/1998	57961	27/May/1998
LEXIVA	Bolivia		19/Nov/1998	78220C	25/Apr/2000
LEXIVA	Botswana	BWM9900008	04/Jan/1999		
LEXIVA	Brazil	821240927	26/Nov/1998	821240927	07/Aug/2007
LEXIVA	Brunei	30512	28/Jun/1999	25702	28/Jun/1999
LEXIVA	Bulgaria	43799	17/Nov/1998	35697	26/May/1999
LEXIVA	Cambodia	11381	27/May/1998	11304	19/Jan/1999
LEXIVA	Chile	433174	18/Nov/1998	541543	28/May/1999
LEXIVA	Colombia	98068443	20/Nov/1998	217926	21/Apr/1999
LEXIVA	Costa Rica		13/Nov/1998	114316	10/Jun/1999
LEXIVA	Croatia	Z981504A	26/Nov/1998	Z981504	22/Feb/1999
LEXIVA	Cuba	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Cyprus	51771	26/Nov/1998	51771	26/Nov/1998
LEXIVA	Czech Republic	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Dominican Republic		18/Nov/1998	102263	15/Feb/1999
LEXIVA	Ecuador	92256	18/Nov/1998	23598	17/Jul/2003
LEXIVA	Egypt	119436	17/Nov/1998	119436	30/Jan/2001
LEXIVA	El Salvador	011998007270	19/Nov/1998	002010120	01/Nov/2000
LEXIVA	Estonia	9802777	26/Nov/1998	31338	20/Jun/2000
LEXIVA	EU	000979294	14/Jun/1999	000979294	14/Feb/2001
LEXIVA	Gambia	2541298	09/Dec/1998		
LEXIVA	Georgia	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Ghana	29636	24/Nov/1998	29636	24/Nov/1998

Trade Mark	Country	Application #	App. Date	Registration #	Reg. Date
LEXIVA	Guatemala	989214	23/Nov/1998	95650	20/May/1999
LEXIVA	Haiti	1324T	22/Mar/1999	185120	25/May/1999
LEXIVA	Honduras	1523698	30/Nov/1998	74804	14/Jul/1999
LEXIVA	Hong Kong	153971998	17/Nov/1998	109791999	27/May/1998
LEXIVA	Hungary	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Iceland	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	India	831149	08/Dec/1998	831149	08/Dec/1998
LEXIVA	Iran	7709143	28/Nov/1998	85263	14/Feb/1999
LEXIVA	Iraq	36929	25/Nov/1998	36929	15/May/2002
LEXIVA	Israel	171672	25/Apr/2004	171672	25/Apr/2004
LEXIVA	Jamaica	57110	25/Nov/1998	34536	25/Nov/1998
LEXIVA	Japan	98298	17/Nov/1998	4321040	01/Oct/1999
LEXIVA	Jordan	51824	22/Nov/1998	51824	01/Feb/2000
LEXIVA	Kenya	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Kuwait	42628	14/Mar/1999	35645	14/Mar/1999
LEXIVA	Laos	6841	27/Nov/1998	5836	14/Jan/1999
LEXIVA	Latvia	M982771	17/Nov/1998	M44979	20/Dec/1999
LEXIVA	Lebanon		21/Nov/1998	77870	21/Nov/1998
LEXIVA	Liechtenstein	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Lithuania	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Malawi	53098	27/Nov/1998	53098	27/Nov/1998
LEXIVA	Malta	29388	18/Nov/1998	29388	18/Nov/1998
LEXIVA	Mexico	355884	27/Nov/1998	607706	29/Apr/1999
LEXIVA	Moldova	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Monaco	703053	23/Nov/1998	703053	23/Nov/1998

Trade Mark	Country	Application #	App. Date	Registration #	Reg. Date
LEXIVA	Montenegro (Republic of)	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Morocco	67948	25/Nov/1998	67948	25/Nov/1998
LEXIVA	Myanmar	6341999	19/Feb/1999	422482007	19/Feb/1999
LEXIVA	Namibia	981632	20/Nov/1998	981632	20/Nov/1998
LEXIVA	New Zealand	301408	17/Nov/1998	301408	27/May/1998
LEXIVA	Nicaragua	9900890	24/Mar/1999	45617	11/Dec/2000
LEXIVA	Nigeria	TP3847996	18/Nov/1998	59804	18/Nov/1998
LEXIVA	Norway	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	OAPI (African Union)	89372	25/Nov/1998	40190	29/Nov/1999
LEXIVA	Oman	19096	22/Nov/1998	19096	26/Jun/2004
LEXIVA	Pakistan	151470	20/Nov/1998	151470	20/Nov/1998
LEXIVA	Panama	097294	16/Nov/1998	97294	16/Nov/1998
LEXIVA	Peru	074673	27/Nov/1998	54441	29/Apr/1999
LEXIVA	Poland	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Romania	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Russian Federation	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Saudi Arabia	47093	12/Dec/1998	52224	27/Feb/2000
LEXIVA	Serbia (Republic of)	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Liechtenstein	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Sierra Leone	16290	26/Jul/1999	16290	18/Oct/2001
LEXIVA	Singapore	T9811544B	18/Nov/1998	T9811544B	27/May/1998
LEXIVA	Slovak Republic	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Slovenia	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	South Africa	09820509	16/Nov/1998	199820509	27/May/1998
LEXIVA	Sri Lanka	90430C	27/May/1998	90430	07/Dec/1998

Trade Mark	Country	Application #	App. Date	Registration #	Reg. Date
LEXIVA	Switzerland	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Syria	70686	21/Nov/1998	866987	25/Jan/2000
LEXIVA	Taiwan	87055789	19/Nov/1998	866987	16/Sep/1999
LEXIVA	Tanganyika (Tanzania Republic)	26642	11/Feb/1999	26642	11/Feb/1999
LEXIVA	Thailand	375273	26/Nov/1998	KOR98496	27/May/1998
LEXIVA	Trinidad and Tobago	28998	24/Nov/1998	28998	02/Nov/2000
LEXIVA	Tunisia	EE981824	16/Nov/1998	EE981824	16/Nov/1998
LEXIVA	Turkey	98016359	18/Nov/1998	201159	18/Nov/1998
LEXIVA	Uganda	22022	24/Nov/1998	22022	24/Nov/1998
LEXIVA	UK	2167790	27/May/1998	2167790	27/May/1998
LEXIVA	Ukraine	98114422	17/Nov/1998	24323	15/Apr/2002
LEXIVA	United Arab Emirates	29032	21/Nov/1998		
LEXIVA	Uruguay	308576	16/Nov/1998	401562	21/Jul/1999
LEXIVA	USA	78205433	21/Jan/2003	2827902	30/Mar/2004
LEXIVA	USA	78312751	13/Oct/2003	2928773	01/Mar/2005
LEXIVA	Vietnam	N983305	25/Nov/1998	33595	22/Mar/2000
LEXIVA	WIPO	703053	23/Nov/1998	703053	23/Nov/1998
LEXIVA	Yemen (Republic of)	13261	22/Nov/1998	10668	19/Aug/1999
LEXIVA	Zambia	75998	20/Nov/1998	75998	20/Nov/1998
LEXIVA	Zanzibar (Tanzania Republic)	44098	14/Dec/1998	8891999	22/Dec/1999
LEXIVA	Zimbabwe	154598	19/Nov/1998	154598	27/May/1998
LEXIVA in katakana (re ki shi ba)	Japan	200397741	05/Nov/2003	4842750	04/Mar/2005
LEXIVA in katakana (re ku shi ba)	Japan	2004037604	20/Apr/2004	4823464	03/Dec/2004
LEXIVA in katakana (re ku shi va)	Japan	200441276	30/Apr/2004	4804362	17/Sep/2004
LEXIVA with arabic	Qatar	19696	17/Nov/1998	19696	11/Sep/2005

TP092780055